Literature DB >> 27311621

Use of Antibiotics Among Patients With Cirrhosis and Upper Gastrointestinal Bleeding Is Associated With Reduced Mortality.

Andrew M Moon1, Jason A Dominitz2, George N Ioannou2, Elliott Lowy3, Lauren A Beste4.   

Abstract

BACKGROUND & AIMS: Prophylactic antibiotics are recommended for all patients with cirrhosis hospitalized for upper gastrointestinal bleeding (UGIB). We evaluated the association between use of antibiotics, outcomes of re-admissions, and mortality in these patients.
METHODS: We performed a retrospective study of 6451 patients with cirrhosis (mean age, 60.6 y) in the Veterans Affairs health care system hospitalized for UGIB from January 1, 2005, through December 31, 2013 (8655 hospitalizations). We collected information on patients' baseline features, hospitalizations, etiology of UGIB, antibiotics given, hospital re-admission within 30 days of discharge, and mortality. We defined timely administration of antibiotics as receipt from 8 hours before admission through 48 hours afterward.
RESULTS: Timely administration of antibiotics occurred during 48.6% of admissions (n = 4210), increasing from 30.6% in 2005 to 58.1% in 2013. Independent predictors of antibiotic receipt included ascites, high model for end-stage liver disease score, esophageal variceal hemorrhage, and administration of octreotide or intravenous proton pump inhibitors. Variables associated with decreased odds of antibiotic provision included black race and nonalcoholic fatty liver disease. In multivariate analysis, timely administration of antibiotics was associated with a reduced 30-day mortality rate (adjusted odds ratio, 0.70; 95% confidence interval, 0.52-0.93; P = .012).
CONCLUSIONS: In a study of patients with cirrhosis and UGIB in the VA health care system, timely administration of antibiotics was associated with a 30% reduction in 30-day mortality. The proportion of patients with cirrhosis and UGIB receiving timely antibiotics nearly doubled from 2005 to 2013, but many patients-particularly those with less-advanced cirrhosis-did not receive this intervention. Targeted efforts are needed to promote the appropriate use of antibiotics among patients with cirrhosis and UGIB.
Copyright © 2016 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MELD; NAFLD; Treatment; VA System

Mesh:

Substances:

Year:  2016        PMID: 27311621     DOI: 10.1016/j.cgh.2016.05.040

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  10 in total

1.  Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis.

Authors:  George N Ioannou; Pamela Green; Elliott Lowy; Elijah J Mun; Kristin Berry
Journal:  PLoS One       Date:  2018-09-27       Impact factor: 3.240

2.  Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.

Authors:  George N Ioannou; Pamela Green; Kathleen F Kerr; Kristin Berry
Journal:  J Hepatol       Date:  2019-05-28       Impact factor: 25.083

3.  Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores.

Authors:  George N Ioannou; Lauren A Beste; Pamela K Green; Amit G Singal; Elliot B Tapper; Akbar K Waljee; Richard K Sterling; Jordan J Feld; David E Kaplan; Tamar H Taddei; Kristin Berry
Journal:  Gastroenterology       Date:  2019-07-26       Impact factor: 22.682

4.  Comparing AIMS65 Score With MEWS, qSOFA Score, Glasgow-Blatchford Score, and Rockall Score for Predicting Clinical Outcomes in Cirrhotic Patients With Upper Gastrointestinal Bleeding.

Authors:  Yi-Chen Lai; Ming-Szu Hung; Yu-Han Chen; Yi-Chuan Chen
Journal:  J Acute Med       Date:  2018-12-01

5.  Hospital Readmissions in Patients with Cirrhosis: A Systematic Review.

Authors:  Eric S Orman; Marwan Ghabril; Thomas W Emmett; Naga Chalasani
Journal:  J Hosp Med       Date:  2018-04-25       Impact factor: 2.960

6.  The Role of Adjuvant Acid Suppression on the Outcomes of Bleeding Esophageal Varices after Endoscopic Variceal Ligation.

Authors:  Cheng-Kun Wu; Chih-Ming Liang; Chien-Ning Hsu; Tsung-Hsing Hung; Lan-Ting Yuan; Seng-Howe Nguang; Jiunn-Wei Wang; Kuo-Lun Tseng; Ming-Kun Ku; Shih-Cheng Yang; Wei-Chen Tai; Chih-Wei Shih; Pin-I Hsu; Deng-Chyang Wu; Seng-Kee Chuah
Journal:  PLoS One       Date:  2017-01-24       Impact factor: 3.240

7.  Antibiotic use in cirrhotic children with acute upper gastrointestinal bleeding: A retrospective study using the pediatric health information system (PHIS) database.

Authors:  Lina Castillo; Sittichoke Prachuapthunyachart; Mel Hall; Shaija Shelby; Ruben E Quiros-Tejeira; Hanh D Vo
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

8.  Trends and Outcomes of Alcoholic Liver Cirrhosis Hospitalizations in the Last Two Decades: Analysis of the Nationwide Inpatient Sample.

Authors:  Hisham Laswi; Abdul-Rahman Abusalim; Muhammad Sheharyar Warraich; Katayoun Khoshbin; Hafeez Shaka
Journal:  Gastroenterology Res       Date:  2022-04-23

9.  Limited effects of antibiotic prophylaxis in patients with Child-Pugh class A/B cirrhosis and upper gastrointestinal bleeding.

Authors:  Te-Sheng Chang; Ying-Huang Tsai; Yi-Heng Lin; Chun-Hsien Chen; Chung-Kuang Lu; Wen-Shih Huang; Yao-Hsu Yang; Wei-Ming Chen; Yung-Yu Hsieh; Yu-Chih Wu; Shui-Yi Tung; Yen-Hua Huang
Journal:  PLoS One       Date:  2020-02-21       Impact factor: 3.240

10.  Assessment of a Deep Learning Model to Predict Hepatocellular Carcinoma in Patients With Hepatitis C Cirrhosis.

Authors:  George N Ioannou; Weijing Tang; Lauren A Beste; Monica A Tincopa; Grace L Su; Tony Van; Elliot B Tapper; Amit G Singal; Ji Zhu; Akbar K Waljee
Journal:  JAMA Netw Open       Date:  2020-09-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.